These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 12431655

  • 1. IL-2 antibody induction and the outcome of pediatric renal transplants.
    Garcia CD, Barros VR, Schneider L, Alves MD, Silveira CG, Garcia VD.
    Transplant Proc; 2002 Nov; 34(7):2914-5. PubMed ID: 12431655
    [No Abstract] [Full Text] [Related]

  • 2. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A, Arnol M, Omahen K, Oblak M, Vidan-Jeras B, Kmetec A, Bren AF.
    Transplantation; 2010 Apr 27; 89(8):1022-7. PubMed ID: 20075788
    [Abstract] [Full Text] [Related]

  • 3. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
    Grego K, Arnol M, Bren AF, Kmetec A, Tomaziĉ J, Kandus A.
    Transplant Proc; 2007 Dec 27; 39(10):3093-7. PubMed ID: 18089329
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation.
    Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber AO.
    Transplant Proc; 2001 Dec 27; 33(1-2):1701-3. PubMed ID: 11267477
    [No Abstract] [Full Text] [Related]

  • 7. Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection.
    Pham K, Kraft K, Thielke J, Oberholzer J, Sankary H, Testa G, Benedetti E.
    Transplant Proc; 2005 Mar 27; 37(2):899-902. PubMed ID: 15848569
    [Abstract] [Full Text] [Related]

  • 8. Anti-interleukin 2-receptor antibodies: a comparative study with polyclonal antibodies in kidney transplantation: preliminary results.
    Martins L, Henriques AC, Dias L, Sarmento AM, Pereira MC, Guimarães S.
    Transplant Proc; 2000 Dec 27; 32(8):2623-5. PubMed ID: 11134730
    [No Abstract] [Full Text] [Related]

  • 9. The role of newer monoclonal antibodies in renal transplantation.
    Vincenti F.
    Transplant Proc; 2001 Dec 27; 33(1-2):1000-1. PubMed ID: 11267163
    [No Abstract] [Full Text] [Related]

  • 10. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A.
    Paediatr Drugs; 2003 Dec 27; 5(10):699-716. PubMed ID: 14510627
    [Abstract] [Full Text] [Related]

  • 11. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors.
    Sánchez-Fructuoso AI, Prats D, Marques M, Ridao N, Conesa J, García Mena M, Torrente J, Barrientos A.
    Transplant Proc; 2003 Aug 27; 35(5):1689-90. PubMed ID: 12962759
    [Abstract] [Full Text] [Related]

  • 12. The outcome of induction therapy with monoclonal antibodies in kidney transplantation among Iranian patients: a prospective study.
    Naderi GH, Mehraban D, Ganji MR, Jafarpouriani M, Latif AH.
    Transplant Proc; 2009 Sep 27; 41(7):2768-71. PubMed ID: 19765430
    [Abstract] [Full Text] [Related]

  • 13. Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups.
    Ekberg H, Bäckman L, Tufveson G, Tydén G.
    Transplant Proc; 1999 Sep 27; 31(1-2):267-8. PubMed ID: 10083102
    [No Abstract] [Full Text] [Related]

  • 14. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients.
    Nair MP, Nampoory MR, Johny KV, Costandi JN, Abdulhalim M, El-Reshaid W, Al-Muzairai I, Ninan VT, Samhan M, Al-Mousawi M.
    Transplant Proc; 2001 Aug 27; 33(5):2767-9. PubMed ID: 11498153
    [No Abstract] [Full Text] [Related]

  • 15. Pediatric renal transplantation under tacrolimus or cyclosporine immunosuppression and basiliximab induction.
    Garcia CD, Schneider L, Barros VR, Guimarães PC, Garcia VD.
    Transplant Proc; 2002 Nov 27; 34(7):2533-4. PubMed ID: 12431513
    [No Abstract] [Full Text] [Related]

  • 16. The role of anti-IL-2 receptor in high-risk kidney transplant patients.
    Jirasiritham S, Sumethkul V, Mavichak V, Lertsithichai P, Jirasiritham S.
    Transplant Proc; 2004 Sep 27; 36(7):2110-2. PubMed ID: 15518764
    [Abstract] [Full Text] [Related]

  • 17. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.
    Pascual J, Marcén R, Ortuño J.
    Nephrol Dial Transplant; 2001 Sep 27; 16(9):1756-60. PubMed ID: 11522853
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The interleukin-2 inhibitors and their role in low-toxicity regimens.
    Nashan B.
    Transplant Proc; 1999 Dec 27; 31(8A):23S-26S. PubMed ID: 10616557
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.